- Alzamend Neuro ( NASDAQ: ALZN ) has announced receipt of a “ Study May Proceed ” letter from the U.S. FDA for a phase I/IIA clinical trial under its Investigational New Drug application for an immunotherapy to treat mild to moderate dementia of the Alzheimer’s type.
- The Co. strongly believe that the ALZN002 patient-specific immunotherapeutic vaccine has the potential to achieve these objectives and bring aid to the millions of Americans afflicted with this devastating disease.
- "We are advancing the process and expect that the first patient will be dosed in the first quarter of 2023.” said said Stephan Jackman, Chief Executive Officer of Alzamend.
- ALZN +4.42% premarket to $1.18.
For further details see:
FDA grants Alzamend Neuro 'Study May Proceed' letter for dementia IND ALZN002